Newark, New Castle, USA, March 16, 2023 (GLOBE NEWSWIRE) -- The global basal cell and squamous cell carcinoma therapeutics market is expected to clock US$ 12.9 billion by 2030, owing to the rising prevalence of basal and squamous cell carcinoma cases and innovations in drug development, globally; states Growth Plus Reports.
Growth Drivers
During the projection period, there will be an increase in demand for innovative basal cell and squamous cell carcinoma therapies due to the rising frequency of non-melanoma cancer and a large increase in the number of patients inoperable globally. Statistics from cancer.net show In the United States, 3.3 million persons have an estimated 5.4 million cases of basal cell carcinoma and squamous cell carcinoma each year. It has been found that older people have a much higher skin cancer risk than the overall population. The demand for efficient drugs to treat non-melanoma skin cancers is expected to rise as more patients reach an advanced stage of the disease and become poor surgical candidates because of weakened immune systems. Thus, the global basal cell and squamous cell carcinoma treatments market would increase during the projected period.
The global basal cell and squamous cell carcinoma therapeutics market has been analyzed from four perspectives: Drug Class, Route of Administration, Distribution Channel, and Region.
Download PDF Brochure of Basal Cell and Squamous Cell Carcinoma Therapeutics Market Size - COVID-19 Impact and Global Analysis with Strategic Developments at: https://www.growthplusreports.com/inquiry/request-sample/basal-cell-and-squamous-cell-carcinoma-therapeutics-market/8167
Excerpts from ‘By Drug Class Segmentation’
Based on drug class, the global basal cell and squamous cell carcinoma therapeutics market has been antineoplastic, hedgehog pathway inhibitors, monoclonal antibodies, and others. The hedgehog pathway inhibitors market has the largest share due to increased regulatory approvals for them as the first line of treatment in significant markets. In addition, the launch of fresh hedgehog pathway inhibitors and the recent approval of fresh drugs in this segment both support the expansion of this market segment throughout the anticipated time frame. For individuals with locally progressed or metastatic basal cell carcinoma, the American Cancer Society and the Canadian Dermatology Association both prescribe Vismodegib (Hedgehog Pathway Inhibitor) (BCC). The monoclonal antibodies sector is anticipated to have significant growth during the projected period due to the growing use of monoclonal antibodies in the treatment of BCC and SCC, as well as new product releases in this market. The treatment for cutaneous squamous cell carcinoma, Libtayo (cemiplimab-rwlc), is predicted to reach peak sales globally, according to investor presentations and annual reports (cSCC).
Excerpts from ‘By Routes of Administration Segmentation’
Based on the route of administration, the global basal cell and squamous cell carcinoma therapeutics market, topical, parenteral, and oral. In the upcoming years, it is projected that the oral segment, which now accounts for the largest market share for treatments for basal cell and squamous cell carcinoma, will expand quickly. It is anticipated that the industry will further expand because of patients' increasing preference for oral drugs and the growing usage of hedgehog pathway inhibitors. The parenteral category made up a comparatively lesser portion of the market. However, throughout the forecast period, parenteral therapies' higher efficacy than other delivery methods and the rising need for monoclonal antibodies are anticipated to drive this segment's rise.
Excerpts from ‘By Region Segmentation’
Based on region, the global basal cell and squamous cell carcinoma therapeutics market has been segmented into:
- North America
- Europe
- Asia Pacific
- Rest of the World
The basal and squamous cell carcinoma treatments market is rapidly expanding in Asia Pacific. China, Australia, and Japan are the main drivers of market expansion. In Japan, there are 20–25 instances of skin cancer per 100,000 people, compared to 11–12 cases in China. Basal cell carcinoma (BCC) accounts for about 80% of instances, followed by squamous cell carcinoma (16%), and melanoma (4%). Chinese and Japanese Asians are more likely to develop BCCs than Asian Indians are to get SCCs as skin cancer. Further, the increasing drug approvals, government regulations, and initiatives to spread awareness regarding cancer diagnosis are all factors leading to the growth of the global basal and squamous cell carcinoma therapeutics market.
Request for Customization – https://www.growthplusreports.com/inquiry/customization/basal-cell-and-squamous-cell-carcinoma-therapeutics-market/8167
Excerpts from ‘Competitive Landscape’
The prominent players operating in the global basal cell and squamous cell carcinoma therapeutics market are:
- Sun Pharmaceutical Industries Ltd.
- Sanofi
- Eli Lilly and Company
- F. Hoffmann-La Roche Ltd.
- Merck & Co., Inc.
- Regeneron Pharmaceuticals Inc.
- Bausch Health Companies Inc.
- Amgen Inc.
- Bristol Myers Squibb
- Bausch Health
- GlaxoSmithKline PLC
- Mylan N.V.
Table of Content
- INTRODUCTION
- Market Ecosystem
- Timeline Under Consideration
- Historical Years – 2020
- Base Year – 2021
- Forecast Years – 2022 to 2030
- Currency Used in the Report
- RESEARCH METHODOLOGY
- Research Approach
- Data Collection Methodology
- Data Sources
- Secondary Sources
- Primary Sources
- Market Estimation Approach
- Bottom Up
- Top Down
- Market Forecasting Model
- Limitations and Assumptions
- PREMIUM INSIGHTS
- Current Market Trends (COVID-19 Perspective)
- Key Players & Competitive Positioning (2021)
- MARKET DYNAMICS
- Drivers
- Restraints/Challenges
- Opportunities
- GLOBAL BASAL CELL AND SQUAMOUS CELL CARCINOMA THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY DRUG CLASS
- Antineoplastic
- Hedgehog Pathway Inhibitors
- Monoclonal Antibodies
- Others
- GLOBAL BASAL CELL AND SQUAMOUS CELL CARCINOMA THERAPEUTICS MARKET - ANALYSIS & FORECAST, BY ROUTE OF ADMINISTRATION
- Topical
- Parenteral
- Oral
Buy this Premium Research Report: https://www.growthplusreports.com/checkout-8167
VALUE PROPOSITIONS RELATED TO THE REPORT:
- Powered with Complimentary Analyst Hours and Expert Interviews with Each Report
- Comprehensive quantitative and qualitative insights at segment and sub-segment level
- Covid 19 impact trends and perspective
- Granular insights at global/regional/country level
- Deep-rooted insights on market dynamics (drivers, restraints, opportunities) and business environment
- Blanket coverage on competitive landscape
- Winning imperatives
- Exhaustive coverage on 'Strategic Developments' registered by leading players of the market
CUSTOMIZATION OPTIONS:
- Distributor Landscape Assessment
- Pricing Intelligence
- Customer Base Assessment
- Investment & Initiatives Analysis
- 'Business Profile' of Key Players
Schedule a call with our analyst: https://appoint.ly/s/salesZ3Jvd3RocGx1c3JlcG9ydHMuY29t/introduction
Visit our report store at - https://www.growthplusreports.com/report-store
Browse related reports:
Yersinia Diagnostics Market by Test (ELISA, Stool Culture, Radioimmunoassay, CT Scan), Technique (DNA Probes, PCR, Immunoassay, Monoclonal Antibodies) - Global Outlook & Forecast 2023-2031
Titanium Dental Implant Market by Product (Endosteal, Subperiosteal), Procedure (Two-stage, Single-stage), End-user (Hospitals & Clinics, Dental Laboratories) - Global Outlook and Forecast 2023-2031
Surgical Drapes & Gowns Market by Product Type (Surgical Drapes, Surgical Gown), Usage (Disposable, Reusable), End-user (Hospitals, Ambulatory Surgical Centers, Others) – Global Outlook & Forecast 2023-2031
Single-Cell Analysis Market by Product (Consumables, Instruments), Application (Cancer, Immunology, Neurology), End User (Academic and Research Laboratories, Biotechnology and Pharmaceutical Companies) – Global Outlook & Forecast 2023-2031
Refractory/Relapsed B-Cell and T-Cell Lymphoma Market by Type (B-Cell Lymphoma, T-Cell Lymphoma), Therapy (Monotherapy, Combination Therapy) – Global Outlook & Forecast 2023-2031
About Us:
Growth Plus Reports is part of GRG Health, a global healthcare knowledge service company. We are proud members of EPhMRA (European Pharmaceutical Marketing Research Association).
Growth Plus portfolio of services draws on our core capabilities of secondary & primary research, market modelling & forecasting, benchmarking, analysis and strategy formulation to help clients create scalable, ground-breaking solutions that prepare them for future growth and success.
We were awarded by the prestigious CEO Magazine as "Most Innovative Healthcare Market Research Company in 2020.
